CLAIMS

1. A process for producing a compound of the following formula (I):



(I)

which process comprises:

(a) treating a compound of the following formula (5):



(5)

with a compound of the following formula (6):



(6)

to generate an intermediate compound of the following formula (7):



(7) ;

(b) treating a compound of formula (7) as defined above with a compound of the following formula (8):



(8) ; and

(c) recovering a compound of formula (I) as defined above.

2. A process according to Claim 1, in which step (a) is conducted in the presence of tetrakis(triphenylphosphine)palladium and potassium carbonate in 1,4-dioxane and water.

3. A process according to Claim 1 or 2, in which step (b) is conducted in dichloromethane in the presence of pyridine and $Cu(OAc)_2.H_2O$.

4. A process according to Claim 1, 2 or 3, which further comprises, prior to step (b), purifying and recrystallizing the intermediate compound of formula (7).

5. A process according to Claim 4, in which the compound of formula (7) is purified by passage through a silica plug.

6. A process according to Claim 4 or 5, in which the compound of formula (7) is recrystallized from ethyl acetate.

7. A process according to any preceding claim, which further comprises producing the compound of formula (5) by treating a compound of the following formula (4):



(4)

with acetic acid.

8. A process according to Claim 7, in which the reaction between the compound of formula (4) and acetic acid is conducted at a temperature of from 40º – 50ºC.

9. A process according to Claim 7 or 8, in which the compound of formula (4) is generated by treating a compound of the following formula (3)



(3)

with a compound of the following formula (9):



(9)

and 1-propylphosphonic acid cyclic anhydride (T_3P®) in dichloromethane, in the presence of *N,N*-diisopropylethylamine.

10. A process according to any preceding claim, which further comprises recrystallizing the compound of formula (I) from ethyl acetate:n-heptane and recovering the recrystallized product.

11. A process according to any preceding claim, which further comprises formulating the resulting compound of formula (I) with one or more pharmaceutically acceptable carriers or diluents to produce a pharmaceutical composition.

12. A compound which is of the following formula (I'):



(I')

13. A compound of the following formula (I) in crystal form:



(I)

in which the crystal form is characterised by the data shown in the XRPD diffractogram of Figure 1, collected using Cu Kα radiation.

14. A pharmaceutical composition comprising a compound as defined in Claim 12 or 13 and one or more pharmaceutically acceptable carriers or diluents.